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Abstract
Human milk oligosaccharides (HMO) constitute the third most abundant class of molecules in breast milk. Since infants lack the
enzymes required for milk glycan digestion, this group of carbohydrates passes undigested to the lower part of the intestinal tract,
where they can be consumed by speciﬁc members of the infant gut microbiota. We review proposed mechanisms for the depletion and
metabolism of HMO by two major bacterial genera within the infant intestinal microbiota, Biﬁdobacterium and Bacteroides
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Introduction
From the moment a newborn leaves the mother’s womb, it
is exposed to an environment full of microbes. An apparently
chaotic succession of bacteria colonizes the sterile niche of
the neonatal gut, and over the course of the ﬁrst year or
two of life the intestine achieves an adult-like microbial com-
position. Aerobic or facultative anaerobic bacteria that are
capable of growth within the oxygen-replete intestine are
favoured early in an infant’s life. Anaerobic bacteria with lim-
ited or no aerotolerance, such as Biﬁdobacterium, Bacteroides
or Clostridium, become established as oxygen levels decrease
over the ensuing months [1]. Many additional factors such as
sanitary conditions, delivery mode or antibiotic use drive the
ﬂuctuations of the microbial community during the ﬁrst
months [1]. Little is known of the mechanisms that connect
these and other relevant factors to microbiota assembly.
Culture-independent enumeration using 16S ribosomal
RNA sequences has revealed that consumption of breast
milk inﬂuences the microbial landscape of the infant gut
[2,3]. Through lactation, the mother provides the infant with
compounds that may act as prebiotics, which selectively
modify gut microbial composition. As potential prebiotics,
these compounds could provide beneﬁcial effects in the gut
and contribute to the well-being of the newborn [4]. In vitro
fermentation studies have clearly demonstrated that human
milk oligosaccharides (HMO), a very abundant class of mole-
cules in breast milk, play a major role in promoting the
growth of biﬁdobacteria and Bacteroides [5]. While most
infants are well equipped to digest lactose present in breast
milk, degradation of HMO requires an extensive set of glyco-
side hydrolases and intestinal membrane transporters that
the infant lacks in the small intestine. Milk glycans pass undi-
gested to the lower part of the intestinal tract and can
enrich the gut microbiota with members that consume com-
plex carboxydrates [6].
More than 200 different oligosaccharide structures have
been found in the milk of a single donor. Each oligosaccharide
has a common lactose reduced end, elongated with units of
N-acetyllactosamine (Galb1-4GlcNAc) or lacto-N-biose I units
(LNB) (Galb1-3GlcNAc). In addition, these glycans can be
fucosylated and/or sialylated (Fig. 1 shows a summary of the
linkages found in branched and linear HMO) [7]. Fucosyl
linkages in these structures are dependent on the action of at
least three different fucosyltransferases in the mother’s
mammary glands, and the presence of a speciﬁc type of
fucosyltransferases is determined by the mother’s secretor
and Lewis genes [8]. For example, non-secretor mothers (i.e.
those that lack a functional fucosyltransferase-2) are unable to
modify HMO with an a-1-2-linked fucose residue. Recent
reviews highlight the complexity of HMO and variation in
HMO content over time and between individuals [7,9].
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To date, two major groups of commensals found in the
infant gut, Biﬁdobacterium and Bacteroides, have been
described as effective consumers of breast milk glycans [5].
The availability of the genome sequences of several Bactero-
ides and Biﬁdobacterium strains and the development of ana-
lytical methods to monitor the depletion of speciﬁc HMO,
such as HPLC chip/time of ﬂight MS technology, have
recently expanded our knowledge of the different strategies
employed by microbes to consume HMO.
Consumption of HMO by Biﬁdobacterium
Biﬁdobacterium acquisition and metabolism of HMO have
been topics of interest in recent years, since this genus has
been found in high concentration in breast-fed infant faeces
[10]. Many biﬁdobacterial genomes encode a large propor-
tion of oligosaccharide processing and transporting genes
clustered within conserved loci. These loci typically contain
regulatory elements, ABC transporters, carbohydrate binding
proteins and glycoside hydrolases. Genome sequence from
the infant commensal Biﬁdobacterium longum subsp. infantis
(Bif. infantis), a strain adept at HMO consumption, reveals
the existence of ﬁve HMO-related loci [11]. The largest of
these clusters (43 kb) contains several glycoside hydrolases,
ABC transporters and extracellular solute binding proteins.
Absence of solute binding proteins in this locus results in the
lack of ability to grow in HMO [12]. Matrix assisted laser
desorption ionization Fourier transform ion cyclotron
resonance (MALDI-FTICR) MS analysis of glycan consump-
tion during growth in breast milk glycans has revealed that
Bif. infantis efﬁciently consumes a subset of HMO. Lacto-N-
tetraose (Galb1-3GlcNAcb1-3Galb1-4Glc) and its isomer
lacto-N-neotetraose (Galb1-4GlcNAcb1-3Galb1-4Glc), which
are considered short-chain oligosaccharides and are consis-
tently present during lactation in very high concentration,
are imported into the Bif. infantis cell [8]. Speciﬁc intracellular
glycoside hydrolases, such as fucosidases, sialidases or galac-
tosidases, degrade the oligosaccharides to generate mono-
saccharides that enter the fructose-6-phosphate
phosphoketolase central metabolic pathway.
Analysis of other biﬁdobacterial genomes suggests a broad
range of strategies for consuming milk glycans different to
the one described for Bif. infantis. Strains belonging to the
species Bif. biﬁdum express the enzyme lacto-N-biosidase,
which is absent in the Bif. infantis genome. Expression of
extracellular lacto-N-biosidase results in the cleavage of
lacto-N-tetraose outside the cells into two disaccharides.
The resulting LNB and lactose units are then imported.
Once imported, the action of lacto-N-biose phosphorylase
converts LNB into the monosaccharides galactose and
N-acetylglucosamine. Other strains of biﬁdobacteria, such as
those belonging to the species Bif. breve or Bif. longum subsp.
longum, are unable to use diverse HMO but can grow using
short chain oligosaccharides, such as lacto-N-neotetraose or
LNB [13].
Consumption of HMO by Bacteroides
Members of the genus Bacteroides constitute a prevalent genus
within the adult Western gut microbiota, and recent studies
conﬁrm that Bacteroides may also dominate the intestinal mic-
robiota of some infants [3]. Bacteroides are known for their
ability to utilize a wide variety of oligosaccharides from the
intestinal environment, including dietary polysaccharides such
as xylan, fructan or starch and host-derived glycans, especially
those associated with intestinal mucus. This extraordinary
saccharolytic ability is attributable to specialized machinery
encoded by the polysaccharide utilization loci (PULs) within
the Bacteroides genomes [14]. PULs often encode sensor regu-
lators, glycoside hydrolases and homologues of two outer
membrane proteins involved in binding and importing starch
(SusC and SusD). Each PUL within a Bacteroides genome
appears to be responsible for sensing and harvesting a distinct
class of oligosaccharide or polysaccharide. PULs are likely to
be involved in the consumption of HMO.
HMO use has been reported for Bacteroides fragilis and
B. vulgatus. Analysis of HMO consumption by MALDI-FTICR
MS shows that, unlike the bias toward use of short-chain
glycans exhibited by Biﬁdobacterium species, Bacteroides
FIG. 1. Summary of HMO structures, based on the work of Wu
et al. [7].
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efﬁciently consume a broad range of HMO glycans [5]. The
more efﬁcient use of HMO by B. fragilis compared with
B. vulgatus suggests that some Bacteroides species may be
better adapted to take advantage of HMO during infant gut
colonization [15]. Whether HMO or other selective forces
have driven the evolution of the HMO use pathways and the
extent of pathway conservation between species are impor-
tant issues that remain to be determined.
The Bacteroides HMO utilization model is summarized in
Fig. 2. Bacteroides bind complex oligosaccharides, such as
mucin glycans, on the cell surface prior to an initial surface
hydrolysis, which enables the transit of a resulting oligosac-
charide through the outer membrane SusC-like porins into
the periplasm for further degradation [15]. We hypothesize
that, due to high structural similarity found between mucin
glycans and HMOs, Bacteroides may follow a similar strategy
to consume HMOs.
Expression of glycoside hydrolases and transporters
appears to be a common theme for milk glycan consumption
by Bacteroides and Biﬁdobacteria [14]. Table 1 summarizes the
carbohydrate active enzymes putatively involved in HMO
consumption encoded in the genomes of four HMO-utilizing
strains: B. fragilis, B. vulgatus, Bif. biﬁdum and Bif. infantis.
Conclusions
Over the course of human evolution, it is likely that signiﬁ-
cant selective pressure has shaped the composition of breast
milk to provide the maximum advantage for the newborn.
Since microbes appear to compete for infant intestinal colo-
nization yet differ in their relative ability to confer ﬁtness
upon the host (e.g. via maturation of the neonatal immune
system or by providing protection against pathogens), it
seems likely that milk content may be optimized to promote
beneﬁcial species. The ability of certain Biﬁdobacterium strains
to efﬁciently use HMO suggests that production of milk oli-
gosaccharides by the mother may be a strategy to ensure
the presence of this group of bacteria in the infant gut. The
consumption of HMO by Bacteroides species suggests that
milk glycans may be attracting multiple groups of intestine-
adapted mutualists to the infant intestine. Bacteroides play an
essential role within the distal gut in the degradation of the
ﬁbre consumed by the adult host. We hypothesize that by
providing HMO the mother ensures the presence of this
group of bacteria in the infant intestine, conferring stability
and adaptability to the microbiota during the transition to a
post-weaning diet, when Bacteroides are required as a major
component of the intestinal microbial community. This possi-
bility is supported by recent metagenomic studies that have
revealed an abundance of plant polysaccharide-degrading gly-
coside hydrolases within the gut microbiomes of breast-fed
infants [2,3].
While the beneﬁcial inﬂuence of breast milk in infant
health is well supported, much work remains to characterize
the important molecules and to understand how they con-
nect to infant health. Current efforts should focus on attain-
ing a mechanistic understanding of the interaction between
host, breast milk and microbial composition. Increased
FIG. 2. Model of accessing HMO by Bacteroides.
TABLE 1. Annotated gene coding for glycoside hydrolases putatively involved in HMO degradation as described at the CAZy
database (http://www.cazy.org)
GH2 GH16 GH18 GH20 GH29 GH33 GH95
Bacteroides fragilis ATCC25285 15 6 2 12 9 3 4
Bacteroides vulgatus ATCC8483 25 1 2 8 8 2 4
Biﬁdobacterium infantis ATCC15697 2 – 1 3 3 2 1
Biﬁdobacterium biﬁdum NCIMB 4117 3 – – 4 1 1 1
The selected glycoside hydrolase families include the following activities: GH2, a-galactosidase; GH16, endo-b-1,4-galactosidase; GH18, endo-b-N-acetylglycosaminidase;
GH20, b-hexosaminidase; GH29, a-1,3/4-fucosidase; GH33, sialidase; GH95, a-1,2-fucosidase.
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knowledge of how oligosaccharides may inﬂuence the gut
composition will be required for developing therapies with
speciﬁc glycans and microbes to optimize the microbial com-
munity when breast milk is not available and to maximize
each newborn’s chance for a healthy life.
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